Quest Diagnostics Incorporated has announced that it will offer a new FDA-cleared blood test for Alzheimer's disease, developed by Fujirebio. This test, based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio, is the first blood-based in-vitro diagnostic test cleared by the U.S. Food and Drug Administration to help identify patients with amyloid pathology associated with Alzheimer's disease. Quest Diagnostics plans to make this test available for both clinical and research use later this summer, offering a less invasive and more convenient option compared to traditional methods. The test is designed for adult patients aged 50 and older who are showing signs of cognitive decline, and it expands Quest's existing AD-Detect™ product line for assessing symptomatic patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.